Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families

Korean Journal of Internal Medicine

Volumn 28, Issue 1, 2013, Pages 45-53

  Kim, Seong Kyu ^a   Bae, Jisuk ^a   Lee, Hwajeong ^a   Kim, Ji Hun ^a   Park, Sung Hoon ^a   Choe, Jung Yoon ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Citrullinated antigen; First degree relative; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; VIMENTIN;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FAMILIAL DISEASE; FAMILY ASSESSMENT; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; SMOKING; ADOLESCENT; ARTHRITIS, RHEUMATOID; BLOOD; CHI SQUARE DISTRIBUTION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEDIGREE; RISK; SOUTH KOREA; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PEDIGREE; PEPTIDES, CYCLIC; REPUBLIC OF KOREA; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; VIMENTIN; YOUNG ADULT;

EID: 84873882296     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.1.45     Document Type: Article

References (30)

1. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233-255.
2. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol 2009;4:417-434.
3. Lee HS, Lee AT, Criswell LA, et al. Several regions in the major histocompatibility complex confer risk for anti- CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol Med 2008;14:293-300.
4. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-986.
5. Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007;39:1431-1433.
6. Baka Z, Buzas E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009;11:238.
7. Mikuls TR, Cerhan JR, Criswell LA, et al. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2002;46:83-91.
8. Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol 1992;31:365-368.
9. Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993;32:903-907.
10. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-37.
11. Kolfenbach JR, Deane KD, Derber LA, et al. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using f irst-degree relatives of probands with RA. Arthritis Rheum 2009;61:1735-1742.
12. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-2749.
13. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specif ic autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-386.
14. Jorgensen KT, Wiik A, Pedersen M, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008;67:860-866.
15. Silman AJ, Ollier B, Mageed RA. Rheumatoid factor detection in the unaffected first degree relatives in families with multicase rheumatoid arthritis. J Rheumatol 1991;18:512-515.
16. Hazelton RA, Cross SM, Robert G, Strachan N. A family study of the prevalence of antibodies to the rheumatoid arthritis associated nuclear antigen (RANA). Br J Rheumatol 1986;25:349-352.
17. Arlestig L, Mullazehi M, Kokkonen H, Rocklov J, Ronnelid J, Dahlqvist SR. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 2012;71:825-829.
18. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-243.
19. Raza K, Mathsson L, Buckley CD, Filer A, Ronnelid J. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. Ann Rheum Dis 2010;69:627-628.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
21. Choi SW, Lim MK, Shin DH, Park JJ, Shim SC. Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci 2005;20:473-478.
22. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239-262.
23. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-1033.
24. Tilleman K, Van Steendam K, Cantaert T, De Keyser F, Elewaut D, Deforce D. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inf lammatory arthritides. Rheumatology (Oxford) 2008;47:597-604.
25. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-2511.
26. Svard A, Kastbom A, Soderlin MK, Reckner-Olsson A, Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 2011;38:1265-1272.
27. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:R119.
28. Nicaise Roland P, Grootenboer Mignot S, Bruns A, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008;10:R142.
29. Song JS, Park GB, Park AJ. Comparison of anti-mutated citrullinated vimentin with anti-cyclic citrullinated peptide and rheumatoid factors for the diagnostic value of rheumatoid arthritis. J Korean Rheum Assoc 2007;14:235-241.
30. Poulsom H, Charles PJ. Antibodies to citrullinated vimentin are a specif ic and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol 2008;34:4-10.